2200 POWELL STREET, EMERYVILLE, CA
XOMA Royalty Corporation Annual Meeting Approves Director Appointments
XOMA Royalty Corporation Enters Merger Agreement with Ligand Pharmaceuticals
Amended material disclosure
To Acquire Royalty, Further Accelerating Profit Growth and Strengthening Position as a Leading Biopharma Royalty Aggregator
Annual Report to Security Holders
Investor Presentation
XOMA Royalty Corporation Completes Acquisition of Generation Bio
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Schedule 13D - Ownership Report
Amended Tender Offer Statement by Third Party